Skip to main content
    T

    Teva Pharma Industries Ltd ADR (TEVA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $42.58
    -1.92 (-4.31%)

    Market Cap: $51.92B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Teva Pharma Industries Ltd ADR (TEVA) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Teva Pharma Industries Ltd ADR (TEVA) trades at 14.4x trailing earnings and 2.9x sales. Its P/E of 14.4x is above its 5-year median of 5.7x. Its forward P/E is 12.6x. The median P/E across 8 similar companies is 19.9x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 14.3% higher over the next year. Its free cash flow yield is 2.5%.

    MultipleValue
    P/E (trailing)14.4x
    Forward P/E12.6x
    Price to sales2.9x
    Price to book6.3x
    EV/EBITDA31.0x
    Price to FCF40.8x
    EV/FCF51.0x
    PEG0.7
    FCF yield2.5%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 206.4% above 4.7x, its P/S is 262.5% above 0.8x and its P/B is 425.0% above 1.2x.

    MultipleCurrent5-year median10-year median
    P/E14.4x5.7x4.7x
    P/S2.9x1.0x0.8x
    P/B6.3x2.4x1.2x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 3.1x in 2021 to 10.8x in 2025. 2025 was the highest of those years.

    Year endPriceP/EP/SP/B
    2025$31.2110.8x2.1x4.6x
    2024$22.048.9x1.5x4.6x
    2023$10.444.1x0.7x1.6x
    2022$9.123.6x0.7x1.3x
    2021$8.013.1x0.6x0.9x
    2020$9.653.8x0.6x1.1x
    2019$9.804.1x0.6x0.8x
    2018$15.425.3x0.8x1.1x
    2017$18.954.7x0.9x1.1x
    2016$36.257.1x1.6x1.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TEVA

    What is TEVA's forward P/E ratio?

    Teva Pharma Industries Ltd ADR has a forward P/E ratio of 12.6x.

    Is TEVA stock overvalued?

    GNG's valuation label for TEVA is Overvalued. Its P/E of 14.4x compares with a median of 19.9x across 8 similar companies.

    What is TEVA's price to sales ratio?

    Teva Pharma Industries Ltd ADR has a price to sales ratio of 2.9x.

    What is Teva Pharma Industries Ltd ADR's average P/E ratio over 5 years?

    Teva Pharma Industries Ltd ADR's median P/E over the last 5 years is 5.7x, from 60 month-end values through Oct 2026.

    What is TEVA's PEG ratio?

    Teva Pharma Industries Ltd ADR has a PEG ratio of 0.7.